3648 results for «501»

Filter By

3648 results

New TAVI platforms - Novel devices, early data

20 May 2026 – From EuroPCR 2026

Explore the latest developments in TAVI technology, featuring novel valve platforms and early clinical data. The session covers outcomes from new self-expandable and balloon-expandable valves, innovative single-operator techniques, redo TAVI approaches, and advances in CT sizing powered by deep learning.

To rescue the unexpected complications during TAVI

20 May 2026 – From EuroPCR 2026

This session focuses on the recognition and management of unexpected complications during TAVI procedures. Through cases from Hong Kong, Kazakhstan, and Uzbekistan, it examines mechanisms underlying common and rare complications such as aortic sinus injury, acute valve dislocation, and left main collapse. Attendees gain practical insights...

Imaging the calcified lesions: what you need to see

20 May 2026 – From EuroPCR 2026

This session emphasizes critical imaging aspects necessary for assessing calcified coronary lesions. It addresses lesion-specific Agatston scoring, OCT-guided PCI optimization, coronary CT planning, histopathological insights, and predictors of stent underexpansion after calcium modification.

Lessons from the long-term DES data: how they can inform today's practice

20 May 2026 – From EuroPCR 2026

This session reviews long-term clinical data on drug-eluting stents (DES) and bioresorbable scaffolds (BRS), offering valuable insights to inform current interventional cardiology practice. It covers seven-year outcomes of magnesium scaffolds in ACS, five-year results of sirolimus-eluting iron BRS, and extensive post-market studies of various thin-strut and...

Major Late-Breaking Trials from EuroPCR 2026

20 May 2026 – From EuroPCR 2026

This session presents major late-breaking trials from EuroPCR 2026, reviewing contemporary evidence on coronary revascularization in TAVI patients, long-term outcomes of PCI versus CABG for left main disease, and comparative effectiveness of LAA closure versus NOAC in atrial fibrillation across age groups, with clinical practice implications.

Major Late-Breaking Trials from EuroPCR 2026

Large-bore mechanical thrombectomy vs catheter-directed thrombolysis for treatment of intermediate-risk pulmonary embolism: primary outcomes from the PEERLESS randomized controlled trial

30 Oct 2024

Elad Asher provides his take on the PEERLESS trial presented by Wissam A. Jaber at TCT 2024 in Washington.

Elad Asher

Author

Elad Asher
Large-bore mechanical thrombectomy vs catheter-directed thrombolysis for treatment of intermediate-risk pulmonary embolism

The PROTECTED TAVR study: Cerebral embolic protection during transcatheter aortic valve replacement

18 Sep 2022

Jonathan Curio provides his take on the PROTECTED TAVR study which was presented by Samir R. Kapadia at TCT 2022. The aim was to evaluate whether TAVR with cerebral embolic protection would reduce the rate of clinical stroke in transfemoral TAVR.

Jonathan Curio

Author

Jonathan Curio
The PROTECTED TAVR study: Cerebral embolic protection during transcatheter aortic valve replacement

Outcomes in patients with atrial fibrillation randomized to receive LAA closure or oral anticoagulation: Primary results of the CHAMPION-AF clinical trial

28 Mar 2026

During the first Late-Breaking Trial session of the 2026 ACC Congress held in New Orleans, Saibal Kar, principal investigator of the CHAMPION-AF trial, presented the 3-year results of this groundbreaking study, which were simultaneously published in the NEJM (DOI: 10.1056/NEJMoa2517213).

Luigi Biasco

Author

Luigi Biasco
CHAMPION-AF: LAAC vs oral anticoagulation in atrial fibrillation
Didn’t find what you were looking for?